Janssen warns of risks of blood clotting disorders after vaccines

Janssen warns of risks of blood clotting disorders after vaccines

Janssen, a part of Johnson and Johnson, warned healthcare professionals in South Africa of the risks of blood clotting disorders triggered by the COVID-19 vaccine, in a medicine safety information announcement released on October 26, 2021. TrialSite has followed the development of this vaccine from its early stages and through its promising clinical trials. However, the October statement highlights the risks of immune thrombocytopenia (ITP) and venous thromboembolism (VTE) following vaccination with the Janssen product.

The Janssen COVID-19 vaccine is approved for use in a number of countries worldwide, including the US, where it was issued Emergency Use Authorization (EUA) in February 2021. Over 15m doses were administered in the US alone by the end of October 2021. The vaccine is popular because of only requiring a single dose, as well as the company’s commitment to releasing the vaccine on a not-for-profit basis.

However, the vaccine’s roll-out has not been smooth. The US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) paused use of the vaccine in April 2021, after six serious advers...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee